Cargando…

Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors

BACKGROUND: Several studies have evaluated the relationship between tumor mutational burden (TMB) and outcomes of immune checkpoint inhibitors. In the phase II KEYNOTE-158 study of pembrolizumab monotherapy for previously treated recurrent or metastatic cancer, high TMB as assessed by the Foundation...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cristescu, Razvan, Aurora-Garg, Deepti, Albright, Andrew, Xu, Lei, Liu, Xiao Qiao, Loboda, Andrey, Lang, Lixin, Jin, Fan, Rubin, Eric H, Snyder, Alexandra, Lunceford, Jared
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Immunotherapy Biomarkers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8804694/ https://www.ncbi.nlm.nih.gov/pubmed/35101941 http://dx.doi.org/10.1136/jitc-2021-003091

Ejemplares similares

Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma
por: Haddad, Robert I, et al.
Publicado: (2022)

Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types
por: Cristescu, Razvan, et al.
Publicado: (2022)

High tumor mutational burden predicts favorable response to anti-PD-(L)1 therapy in patients with solid tumor: a real-world pan-tumor analysis
por: Jung, Jaeyun, et al.
Publicado: (2023)

Evaluation of tumor antigen-specific antibody responses in patients with metastatic triple negative breast cancer treated with cyclophosphamide and pembrolizumab
por: Routh, Eric D, et al.
Publicado: (2023)

Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patients
por: Starzer, Angelika M, et al.
Publicado: (2021)

Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC)
por: Ricciuti, Biagio, et al.
Publicado: (2021)

Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden
por: Florou, Vaia, et al.
Publicado: (2023)

Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer
por: Alessi, Joao V, et al.
Publicado: (2021)

Heterogeneity of tumor immune microenvironment of EGFR/ALK-positive tumors versus EGFR/ALK-negative tumors in resected brain metastases from lung adenocarcinoma
por: Xiao, Gang, et al.
Publicado: (2023)

Changes in circulating tumor DNA and outcomes in solid tumors treated with immune checkpoint inhibitors: a systematic review
por: Al-Showbaki, Laith, et al.
Publicado: (2023)

KLRG1 marks tumor-infiltrating CD4 T cell subsets associated with tumor progression and immunotherapy response
por: Ager, Casey R, et al.
Publicado: (2023)

MRI of tumor T cell infiltration in response to checkpoint inhibitor therapy
por: Jiang, Xiaoyu, et al.
Publicado: (2020)

Identification of tumor-intrinsic drivers of immune exclusion in acral melanoma
por: Augustin, Ryan C, et al.
Publicado: (2023)

Comparison of PD-L1 tumor cell expression with 22C3, 28-8, and SP142 IHC assays across multiple tumor types
por: Maule, Jake G, et al.
Publicado: (2022)

Baseline and post-treatment biomarkers of resistance to anti-PD-1 therapy in acral and mucosal melanoma: an observational study
por: Shui, Irene M., et al.
Publicado: (2022)

Multiparametric MRI of early tumor response to immune checkpoint blockade in metastatic melanoma
por: Lau, Doreen, et al.
Publicado: (2021)

Tumor microenvironment evaluation promotes precise checkpoint immunotherapy of advanced gastric cancer
por: Zeng, Dongqiang, et al.
Publicado: (2021)

Tumor mutation burden for predicting immune checkpoint blockade response: the more, the better
por: Zheng, Ming
Publicado: (2022)

Immunogenomic determinants of tumor microenvironment correlate with superior survival in high-risk neuroblastoma
por: Bao, Riyue, et al.
Publicado: (2021)

Soluble HLA peptidome of pleural effusions is a valuable source for tumor antigens
por: Khazan-Kost, Sofia, et al.
Publicado: (2022)

Analysing the tumor transcriptome of prostate cancer to predict efficacy of Lu-PSMA therapy
por: Handke, Analena, et al.
Publicado: (2023)

Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative breast cancer
por: Chun, Brie, et al.
Publicado: (2022)

Increase in serum choline levels predicts for improved progression-free survival (PFS) in patients with advanced cancers receiving pembrolizumab
por: Watson, Geoffrey Alan, et al.
Publicado: (2022)

Tumor copy-number alterations predict response to immune-checkpoint-blockade in gastrointestinal cancer
por: Lu, Zhihao, et al.
Publicado: (2020)

Mutation burden-orthogonal tumor genomic subtypes delineate responses to immune checkpoint therapy
por: Takamatsu, Shiro, et al.
Publicado: (2022)

Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity
por: Reches, Adi, et al.
Publicado: (2020)

PODO447: a novel antibody to a tumor-restricted epitope on the cancer antigen podocalyxin
por: Canals Hernaez, Diana, et al.
Publicado: (2020)

Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanoma
por: Reschke, Robin, et al.
Publicado: (2021)

m(6)A modification patterns and tumor immune landscape in clear cell renal carcinoma
por: Zhong, Jiehui, et al.
Publicado: (2021)

TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment
por: Kawashima, Shusuke, et al.
Publicado: (2021)

Association of race/ethnicity with innate immune tumor microenvironment of children with B-acute lymphoblastic leukemia
por: Gilbert, Julie R, et al.
Publicado: (2022)

Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma
por: Brown, Landon C, et al.
Publicado: (2022)

Evaluation of tissue- and plasma-derived tumor mutational burden (TMB) and genomic alterations of interest in CheckMate 848, a study of nivolumab combined with ipilimumab and nivolumab alone in patients with advanced or metastatic solid tumors with high TMB
por: He, Jie, et al.
Publicado: (2023)

Early changes in immune cell subsets with corticosteroids in patients with solid tumors: implications for COVID-19 management
por: Marté, Jennifer L, et al.
Publicado: (2020)

Granzyme B PET imaging of immune-mediated tumor killing as a tool for understanding immunotherapy response
por: LaSalle, Thomas, et al.
Publicado: (2020)

Biological and technical factors in the assessment of blood-based tumor mutational burden (bTMB) in patients with NSCLC
por: Schuurbiers, Milou, et al.
Publicado: (2022)

Profiling specific cell populations within the inflammatory tumor microenvironment by oscillating-gradient diffusion-weighted MRI
por: Hoffmann, Emily, et al.
Publicado: (2023)

Impact of immune-related adverse events on the therapeutic efficacy of pembrolizumab in urothelial carcinoma: a multicenter retrospective study using time-dependent analysis
por: Kawai, Taketo, et al.
Publicado: (2022)

Early tumor shrinkage identifies long-term disease control and survival in patients with lung cancer treated with atezolizumab
por: Hopkins, Ashley M, et al.
Publicado: (2020)

CD8(+) TILs in NSCLC differentiate into TEMRA via a bifurcated trajectory: deciphering immunogenicity of tumor antigens
por: Lee, Sung-Woo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jq2rbp0fk81budpfeaenu3a3hf